TABLE 1

Demographic and baseline characteristics (intention-to-treat population)

Patients4324
Age years64.6±8.30
Male2908 (67.3)
Body mass index kg·m−227.6±5.00
Current smokers2292 (53.0)
Duration of COPD years6.1±5.50
mMRC grade
 12591 (59.9)
 ≥21693 (39.2)
BDI total score7.3±1.80
CAT total score13.2±6.50
CCQ total score1.8±0.90
Post-bronchodilator FEV1 L1.85±0.49
Post-bronchodilator FEV1 % pred64.7±8.70
Post-bronchodilator FEV1/FVC0.57±0.08
Exacerbations in previous 12 months
 1867 (20.1)
 ≥216 (0.4)
Baseline treatment
SABA, SAMA or SABA+SAMA496 (11.5)
LABA+ICS (fixed-dose or free combination)1059 (24.5)
LABA (only monotherapy)1193 (27.6)
LAMA (only monotherapy)1512 (35.0)
Others/not applicable/unknown#187 (4.4)

Data are presented as n, mean±sd or n (%). COPD: chronic obstructive pulmonary disease; mMRC: modified Medical Research Council dyspnoea scale; BDI: Baseline Dyspnoea Index; CAT: COPD Assessment Test; CCQ: Clinical COPD Questionnaire; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SABA: short-acting β2-agonist; SAMA: short-acting muscarinic antagonist; LABA: long-acting β2-agonist; ICS: inhaled corticosteroid; LAMA: long-acting muscarinic antagonist. #: LAMA+ICS, LABA+LAMA, ICS monotherapy, LABA+LAMA+ICS (triple), systemic corticosteroids, methylxanthines, roflumilast and others.